iBio develops and offers product applications of its iBioLaunch and iBioModulator platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants.
Type
Public
HQ
Newark, US
Founded
2008
Size (employees)
43 (est)
iBio was founded in 2008 and is headquartered in Newark, US
Report incorrect company information

Key People/Management at iBio

Robert Kay

Robert Kay

Executive Chairman and Chief Executive Officer
James Mullaney

James Mullaney

CFO
Robert Erwin

Robert Erwin

President
Terence Ryan

Terence Ryan

Chief Scientific Officer
Wayne Fitzmaurice

Wayne Fitzmaurice

Vice President, Intellectual Property
Show more

iBio Office Locations

iBio has an office in Newark
Newark, US (HQ)
100 9 Innovation Way
Show all (1)
Report incorrect company information

iBio Financials and Metrics

iBio Revenue

iBio's revenue was reported to be $948 k in FY, 2016 which is a 48.8% decrease from the previous period.
USD

Revenue (Q3, 2018)

353 k

EBIT (Q3, 2018)

(10.3 m)

Market capitalization (11-Jul-2018)

12.8 m

Closing share price (11-Jul-2018)

0.8

Cash (31-Mar-2018)

3.4 m
iBio's current market capitalization is $12.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

205 k1.9 m948 k

Revenue growth, %

803%(49%)

General and administrative expense

3.9 m5 m7.7 m

R&D expense

1.9 m3.5 m3.2 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

Revenue

819 k349 k160 k134 k379 k135 k75 k37 k353 k

General and administrative expense

949 k1.1 m951 k1.1 m1.2 m1.4 m1.7 m2.4 m2.5 m2.4 m2.8 m7.7 m

R&D expense

552 k585 k343 k1.2 m815 k551 k704 k1 m

Operating expense total

(240 k)1.6 m1.3 m2.2 m2 m2 m2.4 m3.5 m3.3 m3.4 m4 m10.6 m
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

3.6 m9.5 m23 m

Inventories

118 k182 k264 k

Current Assets

3.9 m10.1 m23.9 m

PP&E

6 k13 k25.6 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

Cash

3.4 m5.7 m4.3 m3.5 m8.1 m8.4 m6.7 m21.9 m20.1 m16.3 m12.4 m3.4 m

Current Assets

4.6 m6.9 m5.5 m4.1 m9 m9.1 m7.2 m22.7 m20.5 m16.7 m13 m4 m

PP&E

5 k7 k20 k14 k10 k14 k25.8 m25.6 m25.5 m25.8 m25.3 m

Total Assets

7.3 m9.6 m8.2 m6.7 m11.4 m11.4 m9.4 m50.7 m48.1 m44.2 m40.7 m31 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(3.7 m)(6.6 m)(10.7 m)

Depreciation and Amortization

361 k363 k940 k

Inventories

97 k(64 k)(82 k)

Accounts Payable

56 k806 k(125 k)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

Net Income

379 k(1.6 m)(1.3 m)(1.4 m)(1.7 m)(1.8 m)(4.1 m)(3.6 m)

Depreciation and Amortization

92 k184 k537 k412 k826 k1.3 m1.3 m

Accounts Payable

1.1 m516 k815 k171 k190 k342 k53 k(255 k)7 k102 k

Cash From Operating Activities

(1.1 m)(2.8 m)(5.3 m)(2.3 m)(5.8 m)(9.4 m)(10.1 m)
USDY, 2018

Revenue/Employee

8.2 k

Financial Leverage

7.5 x
Show all financial metrics

iBio Operating Metrics

FY, 2016

Patents Issued

67

Patents Pending

19
Show all operating metrics

iBio Revenue Breakdown

Embed Graph

iBio revenue breakdown by geographic segment: 100.0% from United States and 0.0% from Other

Report incorrect company information

iBio Company Life and Culture

Report incorrect company information